Genetics

Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform

Retrieved on: 
Wednesday, March 15, 2023

Inspire Biotherapeutics Inc. (“Inspire”), an emerging biotech company with a mission to create life-saving gene therapies for monogenic and acquired diseases of the lung, is poised to move its novel lung tropic AAV gene therapy into clinical validation.

Key Points: 
  • Inspire Biotherapeutics Inc. (“Inspire”), an emerging biotech company with a mission to create life-saving gene therapies for monogenic and acquired diseases of the lung, is poised to move its novel lung tropic AAV gene therapy into clinical validation.
  • The AAVenger platform has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types in disease-relevant animal models.
  • The platform can be applied to treat cystic fibrosis, interstitial lung disease, pulmonary fibrosis, and other monogenic lung diseases.
  • “Our lead indication is currently fatal in neonates – we are compelled to get this across the finish line!

Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, March 15, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2022.
  • Enrollment in the trial is currently ongoing to provide additional durability data and further support the recommended Phase 2 dose.
  • In November 2022, Adicet announced the appointment of Dr. Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer.
  • In the fourth quarter of 2022, Adicet’s new in-house manufacturing capabilities in its Redwood City facility became operational.

Nebraska Governor Jim Pillen To Keynote Plant Based Product Council’s Inaugural Conference

Retrieved on: 
Wednesday, March 15, 2023

Today, the Plant Based Products Council (PBPC) announced Nebraska Governor Jim Pillen as a keynote speaker at the PBPC 2023 Annual Conference: Circular Solutions .

Key Points: 
  • Today, the Plant Based Products Council (PBPC) announced Nebraska Governor Jim Pillen as a keynote speaker at the PBPC 2023 Annual Conference: Circular Solutions .
  • The keynote will address Nebraska’s bio-ecosystem and the role of renewable chemicals and biobased products in the state’s bioeconomy development plans.
  • “Nebraska agriculture is known for its innovation and world-class products that feed the world and save the planet,” said Governor Pillen.
  • After finishing his education, Pillen returned to Nebraska and opened a small animal and swine consulting practice.

genXtraits Inc. Announces Closing of First Capital Raise

Retrieved on: 
Wednesday, March 15, 2023

genXtraits Inc. (genXtraits) is pleased to announce the closing of its first capital raise.

Key Points: 
  • genXtraits Inc. (genXtraits) is pleased to announce the closing of its first capital raise.
  • The proceeds will be used to consolidate and expand the firm’s intellectual property (IP) portfolio of technology for the genetic control of plant traits.
  • genXtraits is a new California-based crop genomics company, which was founded in late 2022 by plant biotechnology industry veterans.
  • With its unique IP around genome regulation, genXtraits is uniquely positioned to deliver the next generation technology that is vital for crop improvement globally.”

Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results

Retrieved on: 
Wednesday, March 15, 2023

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and reviewed recent business highlights.

Key Points: 
  • Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and reviewed recent business highlights.
  • “With a strong finish to 2022 and a great start to 2023, Silence is well positioned for an impactful year highlighted by our advancing clinical pipeline,” said Craig Tooman, President and CEO of Silence.
  • We remain on-track to report topline data in the fourth quarter of 2023.
  • Company management will host a conference call and webcast today, Wednesday, March 15, 2023, at 8 a.m. EDT / 12:00 p.m. GMT to discuss fourth quarter and full year 2022 results.

Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 15, 2023

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company will present at the American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company will present at the American Association for Cancer Research (AACR) Annual Meeting.
  • This mechanism of action can exploit vulnerabilities in cancer cells, known as DNA damage repair deficiencies, which are common in 25-30% of solid tumors.
  • Based on its synthetic lethality mechanism of action and strong preclinical results, Lantern is targeting advancing LP-184 to a first-in-human Phase 1 clinical trial in mid-2023.
  • Lantern will also be hosting a key opinion leader webinar on synthetic lethality on Tuesday, March 21, 2023 at 12:00 p.m.

Nanite Inc. Receives Up to $2M Investment from CF Foundation to Explore a Novel Method to Deliver Genetic Therapies to the Lung

Retrieved on: 
Wednesday, March 15, 2023

Nanite Inc. announced today an investment from the Cystic Fibrosis Foundation of up to $2 million to develop gene delivery technologies for the lung.

Key Points: 
  • Nanite Inc. announced today an investment from the Cystic Fibrosis Foundation of up to $2 million to develop gene delivery technologies for the lung.
  • One of the most significant challenges in developing new therapies for patients with cystic fibrosis is effective drug delivery.
  • Polymer nanoparticles (PNPs) are an innovative delivery modality and can offer several advantages over other means of genetic therapy delivery into cells.
  • “We’re thrilled to announce this investment from the Cystic Fibrosis Foundation, which we will use to explore a new way to deliver genetic therapies into the lungs of CF patients,” said Sean Kevlahan, CEO and Co-Founder, Nanite.

ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia

Retrieved on: 
Wednesday, March 15, 2023

Patients with PCD have a high burden of morbidity with chronic respiratory infections and bronchiectasis, and often develop respiratory failure.

Key Points: 
  • Patients with PCD have a high burden of morbidity with chronic respiratory infections and bronchiectasis, and often develop respiratory failure.
  • RCT1100 is designed to be a disease-modifying mRNA-based therapeutic for PCD caused by pathogenic mutations in DNAI1, a gene that encodes a protein essential for ciliary movement.
  • The intent is for the mRNA delivery to lead to DNAI1 protein production in target cells and thereby rescue ciliary function.
  • The study is being conducted in New Zealand and ReCode anticipates enrolling approximately 32 healthy adults who will receive a single dose of either placebo or RCT1100.

 54gene Announces Leadership Changes in Mission to Transform Diversity of Genomics Research Data

Retrieved on: 
Wednesday, March 15, 2023

54gene , Inc. a health data technology company on a mission to transform racial disparity in genomics research data globally, today announced leadership changes that position the company to pursue new strategic partnerships and raise additional capital.

Key Points: 
  • 54gene , Inc. a health data technology company on a mission to transform racial disparity in genomics research data globally, today announced leadership changes that position the company to pursue new strategic partnerships and raise additional capital.
  • The following leadership changes were announced:
    Ron Chiarello, PhD, has been appointed CEO after serving as co-CEO since earlier this year.
  • He also founded Jetalon Solutions, Etalon Technologies, and Orion Metrology, and held research positions at Stanford University and Argonne National Laboratory.
  • Most genomic data used for development research today is from Europe and North America, while less than 3% is from Africa.

Resolve Biosciences Announces Appointment of John Stark as Chief Executive Officer

Retrieved on: 
Wednesday, March 15, 2023

Resolve Biosciences, a company pioneering Molecular Cartography™ technology, announced today that it has appointed John Stark as Chief Executive Officer.

Key Points: 
  • Resolve Biosciences, a company pioneering Molecular Cartography™ technology, announced today that it has appointed John Stark as Chief Executive Officer.
  • As part of this transition, Resolve Biosciences’ previous CEO, Jason Gammack, will be leaving the company.
  • Most recently, Mr. Stark was Chief Executive Officer of Quantum-Si (NASDAQ: QSI), a next-generation, single-molecule protein sequencing platform company.
  • “The Board is excited to welcome John to Resolve Biosciences to lead our next chapter of growth and success,” said Peer M. Schatz, co-founder and Chairman of the Board.